These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38736033)

  • 1. Transfer of the Dual Orexin Receptor Antagonist Daridorexant into Breast Milk of Healthy Lactating Women.
    Kaufmann P; Muehlan C; Anliker-Ort M; Sabattini G; Siebers N; Dingemanse J
    J Clin Pharmacol; 2024 Oct; 64(10):1278-1287. PubMed ID: 38736033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment.
    Berger B; Muehlan C; Klein G; Dingemanse J
    Clin Transl Sci; 2021 Nov; 14(6):2132-2138. PubMed ID: 34121345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects.
    Zenklusen I; Dingemanse J; Reh C; Gehin M; Kaufmann P
    Drugs R D; 2024 Mar; 24(1):97-108. PubMed ID: 38472696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The dual orexin receptor antagonist daridorexant does not affect the pharmacokinetics of the BCRP substrate rosuvastatin.
    Zenklusen I; Muehlan C; Ulc I; Liška J; Dingemanse J
    Clin Exp Pharmacol Physiol; 2020 Nov; 47(11):1843-1849. PubMed ID: 32603512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist.
    Berger B; Dingemanse J; Sabattini G; Delahaye S; Duthaler U; Muehlan C; Krähenbühl S
    Clin Pharmacokinet; 2021 Oct; 60(10):1349-1360. PubMed ID: 34002356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lemborexant levels in breast milk after single doses in healthy, lactating women.
    Rawal S; Brimhall D; Aluri J; Cheng JY; Hall N; Moline M
    Br J Clin Pharmacol; 2024 Jan; 90(1):158-163. PubMed ID: 37565541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daridorexant in Insomnia Disorder: A Profile of Its Use.
    Nie T; Blair HA
    CNS Drugs; 2023 Mar; 37(3):267-274. PubMed ID: 36754930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT Analysis.
    Schilling U; Henrich A; Muehlan C; Krause A; Dingemanse J; Ufer M
    Clin Drug Investig; 2021 Aug; 41(8):711-721. PubMed ID: 34331678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy Subjects.
    Berger B; Brooks S; Zuiker R; Richard M; Muehlan C; Dingemanse J
    CNS Drugs; 2020 Dec; 34(12):1253-1266. PubMed ID: 33205362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic and pharmacodynamic interactions between daridorexant, a dual orexin receptor antagonist, and citalopram in healthy subjects.
    Berger B; Kornberger R; Dingemanse J
    Eur Neuropsychopharmacol; 2021 Oct; 51():90-104. PubMed ID: 34098518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of gastric pH and of a moderate CYP3A4 inducer on the pharmacokinetics of daridorexant, a dual orexin receptor antagonist.
    Gehin M; Wierdak J; Sabattini G; Sidharta PN; Dingemanse J
    Br J Clin Pharmacol; 2022 Feb; 88(2):810-819. PubMed ID: 34371524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the novel dual orexin receptor antagonist daridorexant on night-time respiratory function and sleep in patients with moderate chronic obstructive pulmonary disease.
    Boof ML; Dingemanse J; Brunke M; Esselmann A; Heymer P; Kestermann O; Lederer K; Fietze I; Ufer M
    J Sleep Res; 2021 Aug; 30(4):e13248. PubMed ID: 33417730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial.
    Fietze I; Bassetti CLA; Mayleben DW; Pain S; Seboek Kinter D; McCall WV
    Drugs Aging; 2022 Oct; 39(10):795-810. PubMed ID: 36098936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem.
    Ufer M; Kelsh D; Schoedel KA; Dingemanse J
    Sleep; 2022 Mar; 45(3):. PubMed ID: 34480579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea.
    Boof ML; Dingemanse J; Lederer K; Fietze I; Ufer M
    Sleep; 2021 Jun; 44(6):. PubMed ID: 33305817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daridorexant for the treatment of insomnia disorder: findings and implications.
    Dos Santos JBR; da Silva MRR
    Eur J Clin Pharmacol; 2022 Nov; 78(11):1749-1761. PubMed ID: 36098753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The metabolism of the dual orexin receptor antagonist daridorexant.
    Treiber A; Delahaye S; Weigel A; Aeänismaa P; Gatfield J; Seeland S
    Xenobiotica; 2023 Mar; 53(3):173-183. PubMed ID: 36809238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Comprehensive Review of Daridorexant, a Dual-Orexin Receptor Antagonist as New Approach for the Treatment of Insomnia.
    Ziemichód W; Grabowska K; Kurowska A; Biała G
    Molecules; 2022 Sep; 27(18):. PubMed ID: 36144776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder.
    Kunz D; Dauvilliers Y; Benes H; García-Borreguero D; Plazzi G; Seboek Kinter D; Coloma P; Rausch M; Sassi-Sayadi M; Thein S
    CNS Drugs; 2023 Jan; 37(1):93-106. PubMed ID: 36484969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia.
    Roch C; Bergamini G; Steiner MA; Clozel M
    Psychopharmacology (Berl); 2021 Oct; 238(10):2693-2708. PubMed ID: 34415378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.